VRBCF (Virbac) Accounts Payable & Accrued Expense: $199 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VRBCF Virbac SA VRBCF
85 GF Score
Price $383.25
GF Value $449.88
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Virbac Accounts Payable & Accrued Expense?

Virbac VRBCF 85 Accounts Payable & Accrued Expense is $199 Mil as of Jun. 2026. GuruFocus rates VRBCF with a GF Score™ of 85/100 and a GF Value™ of $449.88 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Virbac's quarterly accounts payable & accrued expense increased from Jun. 2025 ($192 Mil) to Dec. 2025 ($198 Mil) and increased from Dec. 2025 ($198 Mil) to Jun. 2026 ($199 Mil).

Virbac's annual accounts payable & accrued expense increased from Dec. 2023 ($158 Mil) to Dec. 2024 ($181 Mil) and increased from Dec. 2024 ($181 Mil) to Dec. 2025 ($198 Mil).

Virbac Accounts Payable & Accrued Expense Historical Data

* Premium members only.

The historical data trend for Virbac's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Virbac Accounts Payable & Accrued Expense Chart

Virbac Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable & Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 158.38 162.95 158.49 180.94 198.15

Virbac Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Accounts Payable & Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 172.05 180.94 192.36 198.15 198.63
VRBCF
85GF Score
Virbac SA VRBCF
Accounts Payable & Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Virbac Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

What does a Accounts Payable & Accrued Expense of $199 Mil mean?
Virbac (VRBCF) has a Accounts Payable & Accrued Expense of $199 Mil as of Jun. 2026. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on Virbac and its competitors.
Is Virbac's Accounts Payable & Accrued Expense too high?
Virbac's current Accounts Payable & Accrued Expense is $199 Mil. Overall, Virbac has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Virbac's Accounts Payable & Accrued Expense compare to LLY and JNJ?
Virbac's Accounts Payable & Accrued Expense of $199 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable & Accrued Expense for a Drug Manufacturers company?
A good Accounts Payable & Accrued Expense depends on the Drug Manufacturers industry context. However, Accounts Payable & Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable & Accrued Expense mean?
A high Accounts Payable & Accrued Expense can signal that a stock is expensive relative to its fundamentals. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on Virbac and its competitors. Virbac's current Accounts Payable & Accrued Expense is $199 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virbac stock overvalued right now?
Based on GuruFocus' analysis, Virbac (VRBCF) is currently considered Modestly Undervalued. The stock's GF Value™ is $449.88, compared to a current price of $383.25 — trading 14.8% below its estimated fair value. The current Accounts Payable & Accrued Expense is $199 Mil. Virbac's overall GF Score™ is 85/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable & Accrued Expense calculated?
Accounts Payable & Accrued Expense is calculated from a company's financial statements. For Virbac (VRBCF), the current Accounts Payable & Accrued Expense is $199 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Virbac (VRBCF) Overvalued in 2026?

Based on GuruFocus' analysis, Virbac stock appears to be undervalued. The current stock price of $383.25 is trading 14.8% below its estimated GF Value™ of $449.88. GuruFocus considers Virbac to be Modestly Undervalued.

Key valuation signals for VRBCF:

  • Accounts Payable & Accrued Expense: $199 Mil
  • GF Value™: $449.88 vs. price of $383.25 (14.8% below fair value)
  • GF Score™: 85/100 with 2 warning signs

No single metric tells the full story. See the VRBCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Virbac Business Description

Address 13e rue, 1ere avenue 2065, LID - BP 27, Carros, FRA, 06511
Virbac SA is a drug manufacturing company with a focus on animal health. The company generates the vast majority of its revenue in Europe, and it also has its presence in Europe, North America, Far East Asia, India, Africa & Middle East (IMEA), Pacific, and Latin America.
85GF Score

Get the complete analysis for VRBCF

Accounts Payable & Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$383.25
Price
$449.88
GF Value